A brand new drug might be more effective at preventing HIV than current methods. Many people take daily oral antiretroviral medication—known as PrEP (pre-exposure prophylaxis)—to protect themselves ...

A new type of PrEP injection, requiring only three injections a year, could be on the way. The FDA approved injections of cabotegravir in 2021 as a form of PrEP, to minimize the risk of acquiring HIV.

Pharma giant Gilead Sciences has revealed the results of its first, Phase 1 trial into a once-a-year PrEP injection. The company revealed its results at this week’s Conference on Retroviruses and ...

Lenacapavir, a twice-yearly injectable antiretroviral, demonstrated 100% effectiveness for preventing HIV acquisition in a large study of young cisgender women in Africa, Gilead Sciences announced ...

The U.S. Food and Drug Administration has approved a highly effective HIV prevention drug that outperforms oral medications in stopping HIV transmission. Developed by Gilead Sciences, the drug ...

Laura holds a Master's in Experimental Neuroscience and a Bachelor's in Biology from Imperial College London. Her areas of expertise include health, medicine, psychology, and neuroscience. Laura holds ...

Six months of prevention -- that's how long Lenacapavir, the new drug for HIV prevention lasts. The Food and Drug Administration approved it last month, and despite its price tag, HIV Alliance says it ...

Wirth is the CEO of Amida Care. Crowley is the director of the O’Neill Institute’s Center for HIV and Infectious Disease Policy at Georgetown Law. In June, a clinical trial showed that a twice-yearly ...

Compared to daily oral pre-exposure prophylaxis (PrEP), lenacapavir reduces the number of new HIV infections by many more; causes slightly fewer serious unwanted effects; and results in little to no ...